MedDataX Logo

Persistence of Immune Response After Vaccination With MCC

NCT ID: NCT00310687

Last Updated: 2014-09-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1244 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-10-31

Study Completion Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Persistence of Immune response after vaccination with MCC

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine

NCT00310713

Prevention of Meningococcal Infection
COMPLETED PHASE4

Kinetics of B Cell Response in Infants Menjugate Vaccination

NCT00310700

Prevention of Meningococcal Infection
COMPLETED PHASE4

Understanding Immunity Persistence After Adolescent MenC Vaccination

NCT01459432

Antibody Persistance After Booster Dose of Men C Vaccine
COMPLETED

Persistence of Antibody Response to N. Meningitidis Group C in Children

NCT00316654

Prevention of Meningococcal Infection
COMPLETED PHASE4

Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age

NCT00310635

Meningococcal Infection
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prevention of Meningococcal Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BLOOD DRAW

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* healthy adolescents vaccinated with Meningococcal C Conjugate vaccine

Exclusion Criteria

* ascertained or suspected disease caused by N. meningitidis
* household contact with individuals with proven N. meningitidis serogroup C infection
* significant acute or chronic infections
* any other serious disease
Minimum Eligible Age

11 Years

Maximum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Vaccines

INDUSTRY

Sponsor Role collaborator

Novartis

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Vaccines - Information Services

Role: PRINCIPAL_INVESTIGATOR

Novartis Vaccines & Diagnostics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital

Headington, Oxfordshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Impact N° 919

Identifier Type: -

Identifier Source: secondary_id

M14P2E1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine
NCT00856297 COMPLETED PHASE3
Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months
NCT00601731 COMPLETED PHASE2
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine
NCT01148017 COMPLETED PHASE3
One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose Boost or Two Catch-Up Doses Starting at 24 Months of Age
NCT01139021 COMPLETED PHASE3
Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine
NCT01345721 COMPLETED PHASE3
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
NCT00311415 COMPLETED PHASE3
Safety and Immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Children Aged 12-59 Months.
NCT00310817 COMPLETED PHASE2
Understanding the Persistence of Immunity After MenC Vaccines
NCT01126996 COMPLETED
Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life
NCT00625677 COMPLETED PHASE4
Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine
NCT00262015 UNKNOWN PHASE4
Immunogenicity, Safety and Tolerability, of Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Premature and Non Premature Children of 3 Months of Age
NCT00310674 COMPLETED PHASE3
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
NCT01717638 COMPLETED PHASE3
A Study to Evaluate the Persistence and Immune Response to a Booster Dose of MenACWY
NCT01018732 COMPLETED PHASE2
Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants
NCT00262002 COMPLETED PHASE2
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
NCT01823536 COMPLETED PHASE4
Persistence of Bactericidal Antibodies in Adolescents and Adults Who Had Received a Single Dose of Menactra® Vaccine
NCT00862277 COMPLETED
Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612
NCT00955682 COMPLETED PHASE3
Study Evaluating the Tolerance of Conjugate Meningococcal C Vaccine in Infants
NCT00314041 COMPLETED PHASE2
Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children
NCT01900899 COMPLETED PHASE3
B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants
NCT00488683 COMPLETED PHASE2
Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
NCT00381615 COMPLETED PHASE2
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
NCT02141516 COMPLETED PHASE3
Can we Reduce the Number of Vaccine Injections for Children?
NCT01129518 COMPLETED PHASE4
Comparison of Two Meningococcal ACWY Conjugate Vaccines
NCT01192997 COMPLETED PHASE2/PHASE3
Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents
NCT00262041 COMPLETED PHASE2